NO961151L - Antistoffer mot CD40 - Google Patents

Antistoffer mot CD40

Info

Publication number
NO961151L
NO961151L NO961151A NO961151A NO961151L NO 961151 L NO961151 L NO 961151L NO 961151 A NO961151 A NO 961151A NO 961151 A NO961151 A NO 961151A NO 961151 L NO961151 L NO 961151L
Authority
NO
Norway
Prior art keywords
antibodies
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
NO961151A
Other languages
English (en)
Norwegian (no)
Other versions
NO961151D0 (no
Inventor
Iii William C Fanslow
Jodee Zappone
Mark Alderson
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO961151D0 publication Critical patent/NO961151D0/no
Publication of NO961151L publication Critical patent/NO961151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO961151A 1993-10-01 1996-03-21 Antistoffer mot CD40 NO961151L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
PCT/US1994/009984 WO1995009653A1 (fr) 1993-10-01 1994-09-02 Anticorps diriges contre le cd40

Publications (2)

Publication Number Publication Date
NO961151D0 NO961151D0 (no) 1996-03-21
NO961151L true NO961151L (no) 1996-03-21

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961151A NO961151L (no) 1993-10-01 1996-03-21 Antistoffer mot CD40

Country Status (15)

Country Link
US (1) US5801227A (fr)
EP (1) EP0724456B1 (fr)
JP (1) JP3675819B2 (fr)
KR (1) KR960704576A (fr)
AT (1) ATE255906T1 (fr)
AU (1) AU686230B2 (fr)
CA (1) CA2172376C (fr)
DE (1) DE69433406T2 (fr)
DK (1) DK0724456T3 (fr)
ES (1) ES2211884T3 (fr)
FI (1) FI961285A0 (fr)
NO (1) NO961151L (fr)
NZ (1) NZ273504A (fr)
PT (1) PT724456E (fr)
WO (1) WO1995009653A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
CA2293740A1 (fr) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2dcr, un recepteur relie au tnf
EP1082141B1 (fr) * 1998-05-23 2005-09-14 Leiden university medical center Anticorps cd40 et ctl peptides pour le traitement de tumeurs
EP1181050A4 (fr) 1999-04-30 2005-05-18 Jolla Inst Allergy Immunolog Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2398998C (fr) 2000-02-01 2014-04-22 Tanox, Inc. Molecules d'activation des apc se liant au cd40
CN1437478A (zh) * 2000-04-25 2003-08-20 Idec药物公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
WO2001083755A2 (fr) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
ATE541860T1 (de) 2000-10-02 2012-02-15 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40 zur therapie von b- zell tumoren
CN100574803C (zh) 2001-01-31 2009-12-30 拜奥根Idec公司 免疫调节抗体在治疗肿瘤性疾病中的用途
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2658221C (fr) * 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-cd40
EP1425040A2 (fr) * 2001-09-14 2004-06-09 Cytos Biotechnology AG Activation in vivo de cellules presentant un antigene en vue d'augmenter les reponses immunes induites par des particules de type virus
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
PT1680141E (pt) * 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
BRPI0618217A2 (pt) * 2005-11-01 2011-08-23 Novartis Ag usos de anticorpos anti-cd40
ES2400660T3 (es) * 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
UA94264C2 (ru) 2006-04-21 2011-04-26 Новартис Аг Стабильная жидкая фармацевтическая композиция, которая содержит антагонистическое моноклональное антитело к cd40
EP2589654A1 (fr) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate Combinaison 'anticorps agoniste CD40/adjuvant synergique d'interféron de type 1, conjugués la contenant et son utilisation comme agent thérapeutique pour améliorer l'immunité cellulaire
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP3925977A1 (fr) 2012-10-30 2021-12-22 Apexigen, Inc. Anticorps anti-cd40 et procédés d'utilisation
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
MY196646A (en) 2015-09-30 2023-04-27 Janssen Biotech Inc Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
CA3021328A1 (fr) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Anticorps agonistes se liant au cd40 humain et leurs utilisations
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
PT724456E (pt) 2004-04-30
CA2172376C (fr) 2008-11-18
CA2172376A1 (fr) 1995-04-13
WO1995009653A1 (fr) 1995-04-13
EP0724456A4 (fr) 1997-07-02
NO961151D0 (no) 1996-03-21
DE69433406D1 (de) 2004-01-22
JP3675819B2 (ja) 2005-07-27
AU7681994A (en) 1995-05-01
FI961285A (fi) 1996-03-20
US5801227A (en) 1998-09-01
DE69433406T2 (de) 2004-10-07
NZ273504A (en) 1997-12-19
FI961285A0 (fi) 1996-03-20
ATE255906T1 (de) 2003-12-15
AU686230B2 (en) 1998-02-05
KR960704576A (ko) 1996-10-09
EP0724456A1 (fr) 1996-08-07
EP0724456B1 (fr) 2003-12-10
JPH09504169A (ja) 1997-04-28
ES2211884T3 (es) 2004-07-16
DK0724456T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
NO961151L (no) Antistoffer mot CD40
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
DE69221147T2 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
FI962958A (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
DE69233735D1 (de) Bindungsdomänen des Delta-proteins
CA2064915A1 (fr) Ligands de fixation du facteur de necrose tumorale
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE68914244D1 (de) Monoklonaler Antikörper.
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DE3586216T2 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NO890116L (no) Monoklonale antistoffer.
AU8471391A (en) Monoclonal antibodies directed against complexes formed by thrombin and thrombin inhibitors
NO903788D0 (no) Monoklonalt antistoff mot protein c.
NO911300D0 (no) Homoklonale antistoffer mot reseptor-fremkalte bindingsseter.
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application